Drugs.com - Clinical Trials

Orforglipron Demonstrated Statistically Significant Efficacy Results and a Safety Profile Consistent with Injectable GLP-1 Medicines in Successful Phase 3 Trial

INDIANAPOLIS, April 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and...

Apr 18, 2025 - 07:47
 0
Orforglipron Demonstrated Statistically Significant Efficacy Results and a Safety Profile Consistent with Injectable GLP-1 Medicines in Successful Phase 3 Trial
INDIANAPOLIS, April 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and...
Read More

Tags:

Previous Article

When Cosworth built its own F1 car - with four-wheel drive

Next Article

Scuffers: How to build a cult brand

Related Posts

U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review

U.S. FDA Accepts Gilead’s New Drug Applications for Twi...

Feb 27, 2025  0

Azer-cel Granted FDA Fast Track Designation in Blood Cancer DLBCL

Azer-cel Granted FDA Fast Track Designation in Blood Ca...

Mar 21, 2025  0

Amgen and Kyowa Kirin Provide Top-Line Results from Rocatinlimab Phase 3 Ignite Study in Adults with Moderate to Severe Atopic Dermatitis

Amgen and Kyowa Kirin Provide Top-Line Results from Roc...

Mar 9, 2025  0